6 research outputs found
Partial trisomy 13q22-qter associated to leukoencephalopathy and late onset generalised epilepsy
The partial trisomy 13q.22 is an uncommon chromosomopathy. We present a case with a partial trisomic component 13q22 and a monosomic component 5p15 from paternal origin. This patient developed early menopause and major neurological disorders as leukoencephalopathy, late onset generalised epilepsy and stroke. She also had fatty acids disturbances and their potential relation to the neurological disorders and early menopause is discussed. The presented case illustrates the phenotype of 13q22-qter in adult age and reaffirms the importance of studying the karyotype of any patient with seizures or leukoencephalopathy particularly when there are associated other clinical features including stroke at a young age, fatty acids disturbances, microcephaly, hypotelorism, short neck, hemangiomata, short fingers or distal swell in thumbs
Plasmatic level of neurosin predicts outcome of mild cognitive impairment
<p>Abstract</p> <p>Background</p> <p>Mild Cognitive Impairment (MCI) is a disorder considered to be a transitional stage from health to dementia. Diagnosis of dementias at these early stages is always troublesome because the pathophysiologic events leading to dementia precede clinical symptoms. Thus, the development of biomarkers that can be used to support the diagnosis of dementias at early stages is rapidly becoming a high priority. We have recently reported the value of measuring plasmatic levels of neurosin in the diagnosis of Alzheimer's disease (AD). The aim of this study is to determine whether measuring plasmatic concentration of neurosin is a valuable test to predict progression of MCI.</p> <p>Methods</p> <p>Plasmatic neurosin concentrations were measured in 68 MCI patients and 70 controls subjects. Blood samples were obtained at the beginning of the study. Sixty six patients diagnosed with MCI were observed for 18 months. In 36 patients a second blood sample was obtained at the endpoint.</p> <p>Results</p> <p>The mean value of plasmatic neurosin concentration differs significantly between MCI patients who converted to Dementia with vascular component, those who converted to AD, or those who remained at MCI stage. The relative risk of developing Dementia with vascular component when neurosin levels are higher than 5.25 ng/ml is 13 while the relative risk of developing mild AD when neurosin levels are lower than 5.25 ng/ml is 2. Increases in the levels of neurosin indicate progression to Dementia with vascular component.</p> <p>Conclusion</p> <p>The measurement of plasmatic neurosin level in patients diagnosed with MCI may predict conversion from MCI to Dementia with vascular component. A single measurement is also valuable to estimate the risk of developing AD and Dementia with vascular component. Finally, repeated measurement of plasmatic neurosin might be a useful test to predict outcome in patients with MCI.</p
Novel Lrrk2-p.S1761R mutation is not a common cause of Parkinson's disease in Spain
This work was supported by grants from the Parkinson's disease Foundation; Department of Veterans Affairs (1I01BX000531), National Institutes of Health (P50 NS062684, R01 NS065070 and R25 TW009345), Fondo de Investigacion Sanitaria (FIS, PI11/00228, PFIS, FI 11/00259, IFIMAV, and WLA 04/11), Instituto de Salud Carlos III (PI11/00093 and PI08/0915), Spanish Ministry of Economy and Competitiveness, European Social Fund, and the Asociación Parkinson Asturias.Peer reviewe